Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROSHARES TRUST (ZBIO) Share-based Compensation: 2023-2024

Historic Share-based Compensation for Zenas BioPharma (ZBIO) over the last 2 years, with Dec 2024 value amounting to $10.8 million.

  • Zenas BioPharma's Share-based Compensation rose 158.04% to $7.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.3 million, marking a year-over-year increase of 275.51%. This contributed to the annual value of $10.8 million for FY2024, which is 209.61% up from last year.
  • Latest data reveals that Zenas BioPharma reported Share-based Compensation of $10.8 million as of FY2024, which was up 209.61% from $3.5 million recorded in FY2023.
  • Over the past 5 years, Zenas BioPharma's Share-based Compensation peaked at $10.8 million during FY2024, and registered a low of $3.5 million during FY2023.
  • Its 2-year average for Share-based Compensation is $7.2 million, with a median of $7.2 million in 2023.
  • Data for Zenas BioPharma's Share-based Compensation shows a peak YoY surged of 209.61% (in 2024) over the last 5 years.
  • Zenas BioPharma's Share-based Compensation (Yearly) stood at $3.5 million in 2023, then skyrocketed by 209.61% to $10.8 million in 2024.